A new study offers a simple yet impactful way to ease treatment discomfort for patients with breast cancer: wait a little longer before administering pegfilgrastim.

Published on March 24 in the Annals of Internal Medicine, the research shows that giving pegfilgrastim 72 hours after chemotherapy significantly reduces the risk and severity of pegfilgrastim-induced bone pain (PIBP), compared to the standard 24- or 48-hour timing.

The study, led by Peiyong Li of Southern Medical University, involved a randomized controlled trial of 159 patients with stage I to III breast cancer. Participants were divided into three groups based on when they received pegfilgrastim following chemotherapy—24, 48, or 72 hours.

The results were striking. Patients in the 72-hour group reported substantially lower bone pain, as measured by the area under the curve (AUC) of daily pain scores over five days. The mean AUC dropped to 6.05 in the 72-hour group, compared to 12.74 and 14.20 in the 24- and 48-hour groups, respectively.

Beyond the first cycle, the benefits persisted. Those receiving the delayed dose continued to experience significantly less pain across subsequent chemotherapy cycles. Notably, the incidence of severe bone pain was dramatically lower in the 72-hour group—just 22.6%, compred to 58.5% and 66.0% in the earlier dosing groups.

Importantly, delaying pegfilgrastim did not compromise its effectiveness. Rates of neutropenia—a key concern during chemotherapy—remained similar across all groups, and no cases of febrile neutropenia were reported.

As chemotherapy cycles progressed, both the frequency and duration of bone pain decreased overall, but the 72-hour timing consistently offered the most relief.

The findings suggest that a small adjustment in treatment timing could make a meaningful difference in patient comfort. “Administration of pegfilgrastim 72 hours after chemotherapy could serve as a viable strategy in clinical practice to improve the overall treatment experience for patients,” the authors concluded.

For patients navigating the challenges of chemotherapy, this shift could offer a welcome reduction in one of its most common side effects.